

29 October 2024

Treatments for Lung Cancer

Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) 8
- Amivantamab <5
- Atezolizumab Monotherapy <5
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel <5
- Atezolizumab subcutaneous <5
- Dabrafenib + Trametinib <5
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 6
- Durvalumab 18
- Gemcitabine <5
- Nintedanib + Docetaxel 5
- Nivolumab <5
- Osimertinib 35
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) <5
- Paclitaxel <5
- Pembrolizumab Monotherapy 82
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) 11
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 40
- Pemetrexed + Platinum (Carboplatin/Cisplatin) 14
- RET Inhibitors (Pralsetinib, Selpercatinib) <5
- Sotorasib <5
- Tepotinib <5
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin <5
- Other active systemic anti-cancer therapy <5
- Palliative care only Not recorded on RISOH

Carboplatin & Vinorelbine XRT	<5
Cisplatin & Vinorelbine	12
Entrectinib	<5
Gemcitabine & Carboplatin	13
Nivolumab/Paclitaxel/Carboplatin	<5
Paclitaxel & Carboplatin	12
Paclitaxel & Carboplatin XRT	8
Pemetrexed Maintenance	<5

29 October 2024

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.